Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial

This publication has 14 references indexed in Scilit:

• A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
  Cancer Chemotherapy and Pharmacology, 1999
• Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study
  Journal of Clinical Oncology, 1999
• 26 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 3. Results of a randomised trial evaluating palliation & quality of life
  Lung Cancer, 1997
• Promising new agents in the treatment of non-small cell lung cancer
  Cancer Chemotherapy and Pharmacology, 1996
• Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer
  Lung Cancer, 1995
• Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
  Journal of Clinical Oncology, 1994
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
  Investigational New Drugs, 1992
• Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer
  Investigational New Drugs, 1990
• Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer.
  Journal of Clinical Oncology, 1988
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958